Bioline Rx Ltd ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.2M-95.9% YoYTTM through 31 Dec 2025
Net Income -$2MTTM through 31 Dec 2025
Free Cash Flow -$8.1MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 83.1% |
| EBITDA Margin | -829.8% |
| Operating Margin | -866.1% |
| Net Margin | -171.7% |
Returns
-8.7%ROE
-5.0%ROA
Balance Sheet Health
Debt / Equity0.38x
Current Ratio1.95x
Net Debt-$11.9Mnet cash position
Cash & Equivalents$3.3M
Quality Metrics
Piotroski F-Score2 / 9
FCF Margin-686.4%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $1.2M
Diluted EPSFY2025: $0.00
Dividend
No dividend
Capital Allocation
Capex Intensity2.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Royalty Revenues | $1.2M | View detailsExpected to grow as Ayrmid continues commercialization of APHEXDA globally (excluding Asia) and Gloria Biosciences develops motixafortide in Asia. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.